Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis
- PMID: 35187011
- PMCID: PMC8854504
- DOI: 10.3389/fmed.2022.837024
Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis
Abstract
Objective: To investigate the seasonal variation of disease onset and presentation in an ethno-geographically homogeneous cohort of patients with anti-MDA5 positive dermatomyositis (DM).
Methods: This was a multi-centered, retrospective cohort study. Adult Chinese anti-MDA5 positive DM patients were identified from the Hong Kong Myositis Registry and the Clinical Data Analysis and Reporting System from 2015 to 2020. Equal number of IIM patients without anti-MDA5 antibody were selected as controls. Line blot immunoassay was used to detect the autoantibodies. The onset of disease, presenting clinical features and subsequent complications were analyzed for any seasonality.
Results: A total of 110 patients with anti-MDA5 positive DM were studied. The mean age at diagnosis was 53.0 ± 12.3 years and the mean follow-up duration was 20.6 ± 23.1 months. Two third of the patients (66%) had the clinically amyopathic phenotype. Most patients (86%) had interstitial lung disease (ILD) and 42% developed rapidly progressive ILD (RP-ILD). The mortality was 40% and the commonest cause was RP-ILD. Chi-square test showed significantly less patients had symptom onset in July to September. However, no particular seasonal pattern was observed in the anti-MDA5 negative IIM controls. RP-ILD occurred more frequently in patients with disease onset in October to December. Anti-MDA5 positive DM patients with disease onset in warmer months (April to September) were more likely to have clinical muscle involvement.
Conclusion: Apparent seasonal patterns were noted in our ethno-geographically identical anti-MDA5 positive DM patients, but not in IIM patients in general. Certain environmental factors, particularly infection, might be implicated.
Keywords: anti-MDA5; dermatomyositis; idiopathic inflammatory myopathy; myositis specific antibody; rapidly progressive interstitial lung disease (RP-ILD).
Copyright © 2022 So, So, Lam, Wong, Ho, Li, Lau and Tam.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.Front Immunol. 2022 May 6;13:879266. doi: 10.3389/fimmu.2022.879266. eCollection 2022. Front Immunol. 2022. PMID: 35603153 Free PMC article.
-
Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.Front Immunol. 2022 Mar 7;13:845988. doi: 10.3389/fimmu.2022.845988. eCollection 2022. Front Immunol. 2022. PMID: 35320936 Free PMC article.
-
Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.J Immunol Res. 2020 Nov 25;2020:2024869. doi: 10.1155/2020/2024869. eCollection 2020. J Immunol Res. 2020. PMID: 33299896 Free PMC article.
-
Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.Rheumatol Int. 2019 Nov;39(11):1971-1981. doi: 10.1007/s00296-019-04398-2. Epub 2019 Aug 2. Rheumatol Int. 2019. PMID: 31375890 Review.
-
Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.Arthritis Care Res (Hoboken). 2013 Aug;65(8):1316-24. doi: 10.1002/acr.21985. Arthritis Care Res (Hoboken). 2013. PMID: 23908005 Review.
Cited by
-
Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis.Skin Res Technol. 2024 May;30(5):e13701. doi: 10.1111/srt.13701. Skin Res Technol. 2024. PMID: 38682785 Free PMC article.
-
Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.J Clin Lab Anal. 2022 Nov;36(11):e24726. doi: 10.1002/jcla.24726. Epub 2022 Oct 12. J Clin Lab Anal. 2022. PMID: 36221983 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous